Rongliflozin

Rongliflozin
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (1R,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-[(1R)-1-hydroxyethyl]-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol;
CAS Number	2035989-50-3 ;
PubChem CID	122660464 ;
UNII	6FP3NST6ZQ ;
ChEMBL	ChEMBL5314927 ;
Chemical and physical data
Formula	C23H27ClO7
Molar mass	450.91 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CCOc1ccc(Cc2cc([C@]34OC[C@]([C@@H](C)O)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1;
	InChI InChI=1S/C23H27ClO7/c1-3-29-17-7-4-14(5-8-17)10-15-11-16(6-9-18(15)24)23-21(28)19(26)20(27)22(31-23,12-30-23)13(2)25/h4-9,11,13,19-21,25-28H,3,10,12H2,1-2H3/t13-,19+,20+,21-,22-,23+/m1/s1; Key:KODGTDKHPNYCCJ-YWRILDCISA-N;

Last updated August 23, 2025

Rongliflozin is an SGLT2 inhibitor developed as a potential treatment for diabetes.^[1]^[2]

References

↑ Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.
↑ Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.

[2] Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.

[1]

[2]

v t e Sodium-glucose transporter modulators
SGLT1 Tooltip Sodium-glucose transporter 1	Inhibitors: Phloretin Phlorizin T-1095 T-1095A
SGLT2 Tooltip Sodium-glucose transporter 2	Inhibitors: Atigliflozin Bexagliflozin Canagliflozin Dapagliflozin Empagliflozin Enavogliflozin Ertugliflozin Henagliflozin Ipragliflozin Janagliflozin Licogliflozin Luseogliflozin Mizagliflozin Phloretin Phlorizin Remogliflozin Sergliflozin T-1095 T-1095A Tofogliflozin Velagliflozin Antisense oligonucleotides: ISIS-388626
SGLT1 Tooltip Sodium-glucose transporter 1 & SGLT2 Tooltip Sodium-glucose transporter 2	Inhibitors: Sotagliflozin
See also: Receptor/signaling modulators

Legal status

Legal status	Investigational
Identifiers
IUPAC name (1R,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-[(1R)-1-hydroxyethyl]-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS Number	2035989-50-3
PubChem CID	122660464
UNII	6FP3NST6ZQ
ChEMBL	ChEMBL5314927
Chemical and physical data
Formula	C₂₃H₂₇ClO₇
Molar mass	450.91 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCOc1ccc(Cc2cc([C@]34OC[C@]([C@@H](C)O)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1
InChI InChI=1S/C23H27ClO7/c1-3-29-17-7-4-14(5-8-17)10-15-11-16(6-9-18(15)24)23-21(28)19(26)20(27)22(31-23,12-30-23)13(2)25/h4-9,11,13,19-21,25-28H,3,10,12H2,1-2H3/t13-,19+,20+,21-,22-,23+/m1/s1 Key:KODGTDKHPNYCCJ-YWRILDCISA-N